Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P.

Arch Gen Psychiatry. 2012 May;69(5):476-83. doi: 10.1001/archgenpsychiatry.2011.1532.

PMID:
22566579
2.

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB.

J Clin Psychiatry. 2010 Feb;71(2):103-8. doi: 10.4088/JCP.08m04818yel. Epub 2009 Nov 3.

3.

Description of long-term polypharmacy among schizophrenia outpatients.

Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J.

Soc Psychiatry Psychiatr Epidemiol. 2013 Apr;48(4):631-8. doi: 10.1007/s00127-012-0586-6. Epub 2012 Sep 25.

PMID:
23007295
4.

Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study.

Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A.

Am J Psychiatry. 2016 Jun 1;173(6):600-6. doi: 10.1176/appi.ajp.2015.15050618. Epub 2015 Dec 7.

PMID:
26651392
5.

Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.

Längle G, Steinert T, Weiser P, Schepp W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R.

Acta Psychiatr Scand. 2012 May;125(5):372-81. doi: 10.1111/j.1600-0447.2012.01835.x. Epub 2012 Feb 9.

PMID:
22321029
6.

National trends in psychotropic medication polypharmacy in office-based psychiatry.

Mojtabai R, Olfson M.

Arch Gen Psychiatry. 2010 Jan;67(1):26-36. doi: 10.1001/archgenpsychiatry.2009.175.

PMID:
20048220
7.

Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort.

Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J.

Arch Gen Psychiatry. 2006 Dec;63(12):1358-67.

PMID:
17146010
8.

Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia.

Haukka J, Tiihonen J, Härkänen T, Lönnqvist J.

Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):686-96. doi: 10.1002/pds.1579. Erratum in: Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1113.

PMID:
18327869
9.

Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study.

Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, Lehrer D, Klein R, Hurst M.

J Clin Psychiatry. 2016 May;77(5):661-7. doi: 10.4088/JCP.15m10271.

11.
12.

Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.

Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Häkkinen U, Isohanni M, Hakko H.

Schizophr Res. 2013 Oct;150(1):274-80. doi: 10.1016/j.schres.2013.07.043. Epub 2013 Aug 14.

PMID:
23953217
13.
14.

All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.

Tenback D, Pijl B, Smeets H, Os Jv, Harten Pv.

J Clin Psychopharmacol. 2012 Feb;32(1):31-5. doi: 10.1097/JCP.0b013e31823f3c43.

PMID:
22198442
15.

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P.

Am J Psychiatry. 2011 Jun;168(6):603-9. doi: 10.1176/appi.ajp.2011.10081224. Epub 2011 Mar 1. Erratum in: Am J Psychiatry. 2012 Feb;169(2):223.

PMID:
21362741
16.

Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.

Molina JD, Lerma-Carrillo I, Leonor M, Pascual F, Blasco-Fontecilla H, González-Parra S, López-Muñoz F, Alamo C.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):10-5. doi: 10.1097/WNF.0B013E3181672213.

PMID:
18978498
17.

Treatments for late-life bipolar disorder.

Aziz R, Lorberg B, Tampi RR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):347-64. Review.

PMID:
17296540
18.

How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective.

Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S.

Pharmacopsychiatry. 2012 Jun;45(4):133-7. doi: 10.1055/s-0031-1297934. Epub 2011 Dec 15.

PMID:
22174025
19.

[Mortality and cumulative exposure to antipsychotics, antidepressants and benzodiazepines in patients with schizophrenia: an observational follow-up study].

Tiihonenl J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A.

Duodecim. 2016;132(2):181. Finnish. No abstract available.

PMID:
26939492
20.

Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005.

Koskinen H, Martikainen JE, Maljanen T.

Clin Ther. 2009 Jun;31 Pt 1:1469-77. doi: 10.1016/j.clinthera.2009.07.003.

PMID:
19698904

Supplemental Content

Support Center